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Abstract
Infantile or early onset is estimated to occur in around 10% of all facioscapulohumeral dystrophy (FSHD) patients. Although small series of
early onset FSHD patients have been reported, comprehensive data on the clinical phenotype is missing. We performed a systematic literature
search on the clinical features of early onset FSHD comprising a total of 43 articles with individual data on 227 patients. Additional data from four
cohorts was provided by the authors. Mean age at reporting was 18.8 years, and 40% of patients were wheelchair-dependent at that age. Half of
the patients had systemic features, including hearing loss (40%), retinal abnormalities (37%) and developmental delay (8%). We found an inverse
correlation between repeat size and disease severity, similar to adult-onset FSHD. De novo FSHD1 mutations were more prevalent than in
adult-onset FSHD. Compared to adult FSHD, our findings indicate that early onset FSHD is overall characterized by a more severe muscle
phenotype and a higher prevalence of systemic features. However, similar as in adults, a significant clinical heterogeneity was observed. Based on
this, we consider early onset FSHD to be on the severe end of the FSHD disease spectrum. We found natural history studies and treatment studies
to be very scarce in early onset FSHD, therefore longitudinal studies are needed to improve prognostication, clinical management and
trial-readiness.
© 2017 Elsevier B.V. All rights reserved.
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1. Introduction
Facioscapulohumeral dystrophy (FSHD) is one of the most
frequent hereditary muscular diseases with an estimated
prevalence of 5–13 in 100,000 [1,2]. In 3–21% of patients the
symptoms start at an early age [3,4]. Currently, two genetically
distinct types of FSHD, called FSHD1 and FSHD2, are known.
In both types, inefficient epigenetic repression of the retrogene
DUX4 plays a key role in the pathogenesis [5,6]. FSHD1
accounts for 95% of all patients and almost all early onset cases
[7], it is associated with contraction of the D4Z4-repeat at
chromosome 4q35 in combination with a disease-permissive
4qA allele [8,9]. In the general population, the number of D4Z4
repeat units varies between 11 to more than 100, while patients
with FSHD1 have only 1–10 repeat units. There is a roughly
inverse correlation between repeat size and disease severity;
most patients with short repeats have a severe disease
phenotype [10,11].
Historically, infantile FSHD was considered a distinct
disease based on clinical onset before the age of two years
(Brooke criteria, 1977 [12]). This concept evolved to early
onset FSHD and was regarded a subgroup of FSHD, defined by
signs or symptoms of facial weakness before the age of 5 and
signs or symptoms of scapular weakness before the age of 10
(Brouwer criteria, 1994 [13]). Whereas the typical, classic form
of FSHD is characterized by slowly progressive, often
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asymmetrical muscle weakness of facial- and shoulder muscles
starting in the second decade of life [3,14], the subgroup of
early onset FSHD patients is characterized by severe muscle
weakness, faster disease progression and systemic features.
These systemic features include epilepsy, mental retardation,
hearing loss, retinal vasculopathy, spinal deformities,
respiratory problems and cardiac arrhythmias [3,13,15–19]. It
should be noted that clinical variability in terms of age at onset
and disease severity is typical of FSHD. Age at onset ranges
from birth to 70 years of age and disease severity may vary
from asymptomatic carriers to patients with severe muscle
weakness causing functional dependence.
Our current understanding of disease severity, systemic
features and prognosis in early onset FSHD is based on small
case-series. Consequently, many questions about the clinical
phenotype and natural history of early onset FSHD remain
unanswered, thus limiting evidence based clinical management.
Here, we systematically review the literature using individual
patient data to gain insight into the clinical spectrum of early
onset FSHD. The ultimate goals are to improve recognition and
understanding of early onset FSHD and to advance clinical
management.
2. Methods
2.1. Search strategy
We searched Embase (index period 1970–2016) and
PubMed (index period 1970–2016) for articles reporting early
onset FSHD cases (Supplementary Appendix A). We applied a
sensitive search strategy using search terms as described in
Table 1. Additional studies of potential interest were searched
via cross-referencing.
2.2. Eligibility screening
We included articles presenting empirical data on early onset
FSHD patients. We excluded conference abstracts, posters,
publications not reporting original data (e.g. reviews, book
chapters) and studies not reported in English. Articles of
potential interest were screened on the basis of title and abstract
after which full-text evaluation was performed on the remaining
articles (R.G.).
After article selection, two authors (R.G. and T.S.)
independently assessed the eligibility of individual patients and
disagreements were resolved by consensus. We included
patients who fulfilled the criteria by Brooke (signs of FSHD
within the first two years of life [12]) or the criteria by Brouwer
(signs or symptoms of facial weakness before the age of five
and signs or symptoms of shoulder weakness before the age of
ten [13]). Cases were excluded if a concomitant, neuromuscular
disease was present.
2.3. Data-extraction
For every reported patient, we collected the following
parameters: demographics (sex, race, age at onset, age at
examination), clinical characteristics (clinical severity, age
at wheelchair dependency, muscle involvement pattern),
systemic features (developmental abnormalities, perinatal
complications, mental capacity, hearing loss, retinal
abnormalities, epilepsy, spinal deformities, respiratory
problems and cardiac problems), and genetic characteristics
(hereditary pattern and repeat length). For assessment of the
clinical severity the Clinical Severity Score by Ricci (‘Ricci
score’ [11]) was used. We obtained the score from the article or
estimated it based on the clinical description. The age corrected
CSS, correcting for age at examination published by van
Overveld [20] was also calculated. The authors from the two
largest cohorts and two other cohorts [4,13,21,22] supplied
additional individual patient data.
2.4. Statistics
Descriptive statistics were performed for continuous and
categorical data as appropriate. We performed exploratory
statistical analyses to assess relations between variables of
demography, disease severity, systemic features and genetic
parameters. We used linear regression if the dependent variable
was continuous and logistical regression for dichotomous
variables. Correction for multiple testing was not applied and
our analyses should be considered as hypothesis generating
[23]. To this end, we only considered relations with p < 0.05 of
potential interest. All statistical analyses were performed using
IBM SPSS (version 22.0, IBM Corp, Armonk, NY).
3. Results
3.1. Search and selection results
The combined searches yielded 953 records, of which 303
were duplicates, leaving a total of 650 unique articles
(Figure 1). This resulted in 43 articles including 1683 patients
of which 227 are early-onset FSHD patients (Table 2).
3.2. Clinical description of early onset FSHD
Mean age at assessment was 18.8 years (range 2–72 years,
SD 11.9 years). Symptoms started at a mean age of 2.8 years
(range 0–5 years, SD 2.8 years). 56/227 of patients (25%)
showed symptoms in the first year of life, mainly facial
weakness resulting in feeding difficulties and less frequently
inadequate eye closure. Perinatal complications (prematurity,
low birth weight, and dysmorphic features) were reported in
five cases (5/99, 5%) and none was related to muscle weakness
of the child.
Table 1
Search terms used in pubmed and embase.
FSHD AND case OR patient OR series
OR OR
facioscapulohumeral
dystrophy
child OR infant OR infantile OR
early-onset OR severe
OR
OR epilepsy OR mental retardation OR hearing
loss
landouzy OR
Coats OR retinal OR teleangiectasis
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At assessment, the mean Ricci-score was 7 out of 10 (SD
2.6) and the mean age-corrected clinical severity score 1040
(SD 800). In general, the pattern of muscle involvement was
similar to the classical FSHD phenotype with facial,
scapulohumeral, axial and peroneal muscle weakness. Forty
percent of patients were wheelchair dependent; the average age
of wheelchair dependency was 17 years (SD 7.8) (Figure 2).
Mean duration from age at onset to wheelchair dependency was
14.6 years (SD 7.8, range 4–37 years). Skeletal deformities
were present in 70% of patients and included lumbar
hyperlordosis (51%), kyphoscoliosis (9%) pectus excavatum
(2%) and multiple deformities (8%).
Approximately 50% of early onset FSHD patients had
systemic features (hearing loss, vision loss, epilepsy,
intellectual disability, pulmonary abnormalities, and cardiac
abnormalities) (Table 3). Of these, approximately two thirds
had a single systemic feature, and the other third had multiple
systemic features. Clinical hearing loss, predominantly high
frequency loss without need of hearing aids was the most
frequent feature (40%), and 7% of patients had subclinical
hearing loss at auditory testing. Clinical vision loss was
described in 13 out of 227 patients (6%) and signs of
retinopathy were detected in 41 of 112 tested patients (37%).
Spirometry results were available for 112 patients, and
decreased percentage predicted forced vital capacity was
detected in approximately one third. Eighteen out of the total
227 patients were on assisted ventilation at the time of
assessment. Cardiac abnormalities were found in 9% of the 93
conducted electrocardiograms in 93 patients, consisting of
incomplete right bundle branch blocks (4 patients), right
ventricular hypertrophy (2 patients), right atrial hypertrophy (1
patient), and 1st degree atrioventricular block (1 patient).
Epilepsy was present in 18 patients (8%); 5 patients had
localization-related (focal) epilepsy, 2 patients had generalized
epilepsy and 11 patients had unclassified epileptic seizures.
Genetic confirmation of the diagnosis FSHD was present in
171 of 227 reported cases. For 93 patients, DNA from parents
was available. In 68 out of these 93 families, a ‘de novo’
mutation was found (73%). The mean repeat length was 14.2
Kb (SD 4.8, range 9–31). Eleven out of 93 patients were mosaic
(12%).
3.3. Associations with disease severity
A complete overview of all calculated associations between
disease variables is shown in Supplementary Appendix B. We
here focus on the clinically most relevant associations. A
shorter D4Z4 repeat length was associated with a higher age-
corrected clinical severity score (standardized beta -0.202,
PubMed results
N = 409
EMBASE results
N = 538
Title and Abstract Screening
605 potentially relevant articles
Duplicates
N = 303
Full-text Evaluation
137 potentially relevant articles
No clinical FSHD 
articles
N = 513
43 Articles including a total of 1683 patients
No clinical 
empirical data
N = 94
Individual cases included in review
n = 227
Cases excluded
1. Not early onset 
FSHD (n = 1450)
2. Concomitant
disease (n = 6)
Fig. 1. Flow-chart of study and case selection.
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p = 0.019), more wheelchair dependency (OR 0.178,
p = 0.035), more hearing loss (OR 0.254, p = 0.002), and more
epilepsy (OR 0.205, p = 0.014). An earlier age at onset is
correlated with more frequently hearing loss (OR 0.827,
p = 0.001) and hearing loss is correlated with vision loss (OR
6.370, p = 0.007) and intellectual disability (OR 2.272,
p = 0.028). Intellectual disability is associated with epilepsy
(OR 80.0, p = 0.000). Wheelchair dependency is associated
with skeletal deformities (OR 1.855, p = 0.034) and with
assisted ventilation (OR 4.839, p = 0.000).
4. Discussion
Based on data from 227 early onset FSHD cases, we
conclude that early onset FSHD is on the severe end of the
FSHD spectrum. The genetic defect, the distribution pattern of
muscular weakness and the type of systemic features are similar
to the classical FSHD phenotype. Early onset FSHD
distinguishes itself from the adult-onset patients by a more
severe muscle weakness, more rapid progression and more
frequently occurring systemic features. Some systemic features
(cognitive disability, epilepsy) are only associated with early
onset FSHD.
Early onset FSHD patients demonstrate high CSS scores
(mean 7.35, SD 2.6; median 7, IQR 5.5–10) and age corrected
CSS (mean 1008, SD 645; median 842, IQR 571–1273). Of note,
standard deviations and interquartile ranges are indicative of
substantial clinical variation that is characteristic of FSHD.Also,
these severity scores have not been validated in early onset
Table 2
Summary of included articles.
First Author[ref] Year Country Study type #iFSHD #cases Selection criteria Genetic confirmation
Hanson [24] 1971 USA Case-series 3 3 iFSHD
Carroll [25] 1979 USA Case-series 11 11 iFSHD
Taylor [26] 1982 USA Case-series 2 2 iFSHD + retinopathy
Wulff [27] 1982 USA Case-report 1 1 iFSHD
McGarry [28] 1983 USA Case-report 2 2 iFSHD
Meyerson [29] 1984 USA Case-report 2 3 iFSHD + hearing loss
Gieron [30] 1985 USA Case-report 3 4 iFSHD
Gurwin [31] 1985 GBR Case-report 3 4 iFSHD
Korf [32] 1985 USA Case-series 6 6 iFSHD + hearing loss
Bailey [33] 1986 USA Case-report 1 8 iFSHD
Voit [34] 1986 DEU Case-series 7 10 iFSHD + hearing loss
Yasukochi [35] 1988 JPN Case-series 2 2 iFSHD + retinopathy
Shapiro [36] 1991 USA Case-series 9 9 iFSHD
Kamata [37] 1993 JPN Case-report 1 1 iFSHD
Brouwer [13]* 1994 NLD Case-series 6 6 iFSHD †
Jardine [38] 1994 GBR/DEU Case-series 19 27 iFSHD †
Brouwer [21]* 1995 NLD Case-series 4 4 iFSHD
Je Hyeon [39] 1995 JPN Case-report 1 1 iFSHD †
Nakagawa [40] 1996 JPN Case-report 1 2 iFSHD †
Nakagawa [40] 1997 JPN Population cohort 7 42 FSHD †
Okinaga [41] 1997 JPN Case-series 2 3 iFSHD †
Funakoshi [15] 1998 JPN Population cohort 20 127 FSHD ‡
Miura [42] 1998 JPN Case-series 2 2 iFSHD †
Lapena [43] 2001 AUS Case-series 1 1 Vocal cord paralysis ‡
Dorobek [44] 2004 POL Case-report 1 2 iFSHD ‡
Wohlgemuth [45] 2004 NLD Case-series 4 10 FSHD + assisted ventilation ‡
Felice [46] 2005 USA Case-report 2 3 iFSHD ‡
Bindoff [47] 2006 NOR Case-series 2 2 iFSHD ‡
Klinge [16] 2006 GBR Case-series 7 7 iFSHD ‡
Saito [48] 2007 JPN Case-report 1 1 iFSHD
Shields [49] 2007 USA Case-report 1 1 iFSHD ‡
Kolski [50] 2008 CAN Case-report 1 1 iFSHD ‡
Kriswalsky [51] 2008 USA Case-report 1 1 iFSHD ‡
Trevisan [17] 2008 ITA Case-series 5 7 iFSHD + 10-13Kb ‡
Lee [52] 2009 JPN Case-report 1 1 iFSHD ‡
Grosso [53] 2011 ITA Case-report 3 7 iFSHD ‡
Sakellariou [54] 2012 GRE Population cohort 3 127 FSHD ‡
Wang [55] 2012 TWN Population cohort 7 24 FSHD ‡
Chen [19] 2013 TWN Case-series 9 9 iFSHD + 10-13Kb ‡
Statland [56] 2013 USA Case-series 3 10 FSHD + retinopathy ‡
Kana [57] 2013 JPN Case-report 1 1 iFSHD ‡
Dorobek [4]* 2015 POL Population cohort 22 103 FSHD ‡
Nikolic [22]* 2016 ITA Population cohort 36 850 FSHD + 1–3 D4Z4 RU ‡
* Additional data provided by the authors.
† Southern blot p13E.
‡ Double digested EcoRI/BlnI.
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FSHD populations. However, the percentage of early onset
patients being wheelchair-dependent (40%) versus that in the
general FSHD population (6.4% [58]) underscores the severe
muscle weakness in the former group. This is reflected by the
high prevalence of spinal deformities, especially lumbar
hyperlordosis, indicative of early axial weakness. Respiratory
abnormalities are associated with spinal deformities in this and
other studies. Therefore, the higher prevalence of assisted
ventilation in our early onset population (8%) versus the general
FSHD populations (0–7%) is not surprising [45,59,60]. The
latter findings underline the need for regular pulmonary
monitoring by spirometry in early onset FSHD patients [61]. In
addition, we confirm the progressive nature of FSHD in the early
onset population (Supplementary Appendix B; wheelchair
dependency and respiratory failure increase with age).
Furthermore, systemic features occur frequently in early
onset FSHD. The most frequent systemic feature in this
population was hearing loss (40%). It was characterized by
sensorineural loss of preferentially higher frequencies of
limited severity, and hearing aids are usually not necessary. The
frequency of hearing loss in the general FSHD population is
unclear due to widely varying frequencies (ranging from no
association to 64% in selected populations, mean 15%
[18,61–64]. The high frequency of hearing loss underscores the
need for screening hearing function by audiometry, especially
during speech development.
We found a lower prevalence of subclinical retinopathy
(37%) than reported in literature (50–75%) [64,65], This is
probably due to suboptimal screening methods (no fluorescence
angiography). Another explanation might be the later onset of
retinal abnormalities. We did find a higher rate of clinical vision
loss compared to the general FSHD population (6% vs. 0.8%–
1.7% [56,64]). Of note, this percentage is significantly higher
than previously reported.
Electrocardiographic anomalies were present in 9% of early
onset FSHD patients, a prevalence roughly corresponding to
literature on the general FSHD population (albeit being very
heterogenic (range 0–60% [61,66–68], for an overview see
Tawil et al [61].) and consisted of arrhythmia and other minor
abnormalities. The clinical consequences of arrhythmia seem to
be minor since none of the patients required pacemaker
intervention. Interestingly, we found electrocardiographic
changes mainly in patients of Asian origin. This geographic
difference has not been previously reported and deserves
attention in future studies, especially because we also found
significantly different prevalence of mental impairment and
epilepsy between patients from Caucasian and Asian descent.
We found a high percentage of ‘de novo’ mutations in the
early onset FSHD patients: 73% versus 30% in the general
FSHD population [69]. Presumably, severe muscular weakness
limits procreation in early onset FSHD patients. Of note, we did
not find significant differences between early onset patients
with ‘de novo’ mutations versus those with a positive family
history. An association between repeat length and the age-
corrected disease severity score previously reported in the
general FSHD population [70], could be confirmed in the early
onset FSHD patients.
4.1. Limitations and future directions
Besides its strength of a multinational systematic review of
individual patient data on a large number of patients, this study
has a number of limitations. Case reports and case series bear the
potential of publication and selection bias, which might lead to
0
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Fig. 2. Age at loss of ambulation from subgroup of wheelchair dependent
patients (n = 78). Mean age is 17 years (standard deviation 7.8 years).
Table 3
Patient characteristics of published early onset FSHD cases (n = 227).
Demographics
Age at reporting (yrs) 18.8 ± 11.9
Male sex – no. 103 (45%)
African background – no./total no.* 2/227 (1%)
Asian background – no./total no.* 56/227 (25%)
Caucasian background – no./total no.* 169/227 (74%)
Clinical history
Perinatal complications – no./total no. 5/99 (5%)
Age at onset – mean (yrs)† 2.8 ± 2.8
Clinical severity score (CSS) – mean ± SD 7.4 ± 2.6
Age corrected CSS – mean ± SD 1042 ± 800
Wheelchair dependency – no./total no. 87/217 (40%)
Age at wheelchair dependency (yrs) 17.2 ± 7.8
Systemic symptoms
Hearing loss – no./total 91/227 (40%)
Subclinical hearing loss – no./total no. 15/210 (7%)
Retinopathy – no./total no. 41/112 (37%)
Vision loss – no./total no. 13/227 (6%)
Epilepsy – no./total no. 18/227 (8%)
Developmental delay- no./total no. 35/227 (15%)
ECG abnormalities – no./total no. 8/93 (9%)
Spinal deformities – no./total no. 105/152 (70%)
Decreased forced vital capacity (%FVC) - no./total no. 37/121 (31%)
Assisted ventilation – no./total no. 18/227 (8%)
Genetic characteristics
Repeat length – mean (range, SD) 14.2 Kb (9–31 Kb, 4.8)
De novo mutations – no./total no. (%) 68/93 (73%)
Mosaic inheritance– no./total no. (%) 11/93 (12%)
* Based on study location.
† as reported by the parents/caregivers.
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overestimation of the severity of disease and prevalence of
systemic features. Inclusion criteria in some of the included
studies, such as selection of patients with short repeat lengths or
those with hearing difficulties, increases such bias. Moreover,
utilizing the criteria for early onset/infantile FSHD by Brooke
and Brouwer, which address motor symptoms, leads to the
possible exclusion of patients with atypical (i.e. non-motor)
onset of FSHD; we are aware of cases with a retinal vasculopathy
presentation [47,71]. Due to the cross-sectional nature of the
current review and the studies included herein, we remain
unaware on the longitudinal course of early onset FSHD. The
average age at assessment was approximately 18 years.
Considering the progressive nature of the disease and the fact
that these patients are on the severe end of the FSHD spectrum,
progressive handicap and complications could be expected. The
nature of our data and the limitations discussed above underline
the need for well designed, larger longitudinal cohort studies in
early onset FSHD. Such studies are underway and have the
potential of improving the prognostication and classification of
early onset FSHD patients [72,73]. For now, classification on the
basis of age of onset has practical utility both in clinical practice
and clinical trials; the authors therefore recommend using the
criteria by Brouwer to define early-onset FSHD.
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